BiotechTube
Home/Pipeline/BAFFR Allo CAR-NK Cells

BAFFR Allo CAR-NK Cells

B-cell malignancies

Pre-clinicalActive

Key Facts

Indication
B-cell malignancies
Phase
Pre-clinical
Status
Active
Company
PeproMene Bio

About PeproMene Bio

PeproMene Bio is a private, clinical-stage biotech focused on developing BAFF-R-targeting immunotherapies for B-cell cancers and autoimmune disorders. Its lead asset, PMB-CT01 (BAFFR CAR-T), is in Phase 1 trials for relapsed/refractory B-ALL and mantle cell lymphoma, with early clinical data showing promise. The company leverages foundational intellectual property from City of Hope and MD Anderson and is supported by strategic partnerships and investment, positioning it to address antigen escape in CD19-targeted therapies.

View full company profile

Therapeutic Areas

OncologyAutoimmune Disorders

Other B-cell malignancies Drugs

DrugCompanyPhase
CAR-T Program (Hematological)XellSmartPhase 1
IKS03Iksuda TherapeuticsClinical
TNB-486Ancora BioPhase 1
docirbrutinib (AS-1763)Carna BiosciencesPhase 1b
AbivertinibSorrento TherapeuticsPhase 1/2
Kymriah® (tisagenlecleucel)NovartisApproved
KITE-363Gilead SciencesPhase 1/2
HSK29116Haisco Pharmaceutical GroupPhase I/II
TG-1701TG TherapeuticsPhase 1
TG-1801TG TherapeuticsPhase 1
REC-3565Recursion PharmaceuticalsPhase 1
Plamotamab (XmAb®13676)XencorPhase 2